Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924240 | 1.00 | ABCB1 (0.32) | ABCB1CTSD | |
| SCHEMBL5207835 | 1.00 | ABCB1 (0.32) | ABCB1CTSD | |
| SCHEMBL5924497 | 0.82 | — | — | |
| SCHEMBL5924319 | 0.79 | KDM4E (0.41) | CTSD | |
| SCHEMBL16080204 | 0.77 | ABCB1 (0.30) | ABCB1 | |
| SCHEMBL25484894 | 0.77 | CTSD (0.32) | ABCB1CTSD | |
| SCHEMBL24443112 | 0.77 | — | — | |
| SCHEMBL24743669 | 0.74 | PLA2G10 (0.31) | — | |
| SCHEMBL15359750 | 0.69 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL10326860 | 0.69 | AHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230357253-A1 | AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-09 | — | — | US | disclosed |
| US-20230346781-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-05 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070088163-A1 | Modulators of calcitonin and amylin activity | KEMIA, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070088163-A1 | Modulators of calcitonin and amylin activity | KEMIA, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070088163-A1 | Modulators of calcitonin and amylin activity | KEMIA, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| WO-2005025504-A2 | MODULATORS OF CALCITONIN AND AMYLIN ACTIVITY | KEMIA, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-5534540-A | CROSSLINKING AND DISCOLORATION INHIBITION; PRESERVING FOODS; AGING RESISTANCE | ALTEON INC. (US) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | NAMPT, NNMT, NAPRT | ABCB1 3132/4885CTSD 948/4885 |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | ABCB1 4361/4885CTSD 3411/4885 |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | ABCB1 2521/4885CTSD 348/4885 |
| US-20070088163-A1 | Modulators of calcitonin and amylin activity | CALCRL, CALCR, CALCA | ABCB1 3860/4885CTSD 110/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | ABCB1 1492/4885CTSD 955/4885 |
| US-20230346781-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS AND MESENCHYMAL CANCER TYPES | VIM, CDH1, BRCA1 | ABCB1 1036/4885CTSD 1597/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | ABCB1 640/4885CTSD 427/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | ABCB1 115/4885CTSD 3813/4885 |
| US-20230357253-A1 | AGONISTS OF STIMULATOR OF INTERFERON GENES STING | STING1, IRF3, CGAS | ABCB1 2730/4885CTSD 2813/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ABCB1 601/4885CTSD 3143/4885 |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | ABCB1 1186/4885CTSD 4096/4885 |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | ABCB1 852/4885CTSD 26/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | ABCB1 3446/4885CTSD 4213/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | ABCB1 2853/4885CTSD 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.